stockrow
Friday 6 November 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
31.60
2.02
+6.83%
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Total debt
Cogent Biosciences, Inc.'s total debt at the end of fiscal 2025 was $222.9M, up 1,123.0% from $18.2M in fiscal 2022. At the end of the quarter to 30 June 2026 it was $223.5M. Over the past ten years it has ranged from $831.0K (fiscal 2021) to $222.9M (fiscal 2025) — the current reading is the highest in ten years. Cogent Biosciences, Inc. ranks 53rd of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $222.9M | 1,122.95% |
| FY2022 | $18.2M | 2,093.26% |
| FY2021 | $831.0K | (73.66%) |
| FY2020 | $3.2M | (28.51%) |
| FY2019 | $4.4M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $223.5M | 0.13% |
| Mar 2026 | $223.2M | 0.12% |
| Dec 2025 | $222.9M | 403.72% |
| Sep 2025 | $44.3M | 148.19% |
| 19 more quarters | Free account |
Against its own ten years
Low $831.0K
High $222.9M
Ten-year median
$4.4M
Current reading's percentile
100
Total debt against peers
| Company | Total debt |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $2.8B |
| TVTX Travere Therapeutics, Inc. compare | $603.5M |
| CRSP CRISPR Therapeutics AG compare | $586.9M |
| COGT Cogent Biosciences, Inc. | $223.5M |
| SRRK Scholar Rock Holding Corporation compare | $196.2M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| ERAS Erasca, Inc. compare | $56.8M |
| DNTH Dianthus Therapeutics, Inc. compare | $670.0K |
| MANE Veradermics Incorporated compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement